Marksans Pharma Ltd
MARKSANSMarksans Pharma Ltd's earnings have outrun its stock. EPS grew +9.8% in a year against a +4.4% price move.
Biggest watch item: the P/E sits at the 69th percentile of its own range — the multiple has already done part of the work.
The price is in a confirmed uptrend (8 weeks in) while the P/E sits at the 69th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +63.7% year on year, and 80% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Marksans Pharma Ltd trades at ₹267, in a confirmed uptrend and 8 weeks into that stage. That is +26.3% against its own 200-day average. It sits at 95% of a 52-week range of ₹163 to ₹272. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 23 straight weeks.
Today the stock is in a confirmed uptrend — week 8 of stage 2, confirmed. At ₹267 it trades +26.3% versus its 200-day average and sits at 95% of its 52-week range (₹163–₹272).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +428% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 23 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 69th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Marksans Pharma Ltd trades at 26.7× P/E, mid-range by its own standards (69th percentile). Its long-run median P/E is 20.9×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 26.7× is mid-range by its own standards (69th percentile), against a long-run median of 20.9× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +9.8% against a +4.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +24.8%/yr price move, ~+9.6%/yr came from earnings growth and ~+15.2 pp from the multiple (expanding); over 10y, of the +19.1%/yr price move, ~+22.0%/yr came from earnings growth and ~−2.9 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Marksans Pharma Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 19.2% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +12.5% | +16.8% | +16.5% | +12.7% |
| Profit | +9.7% | +16.6% | +11.9% | +17.6% |
| EPS | +9.8% | +16.2% | +9.9% | +17.0% |
| Share price | +4.4% | +37.2% | +24.8% | +19.1% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
58.7/100 — rank 11 of 43 in Pharma - Formulators · 83% evidence confidence
Marksans Pharma Ltd scores 58.7 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20.1 + 17.9 + 11.6 + 9.1 = 58.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Marksans Pharma Ltd reported ₹856 Cr of revenue in the Mar 26 quarter, +20.9% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 12.7% a year. The last full year, FY26, came in at ₹2,951 Cr. The last four reported quarters add to ₹2,950 Cr.
Marksans Pharma Ltd reported ₹856 Cr of revenue in the Mar 26 quarter, +20.9% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 12.7% a year. The last full year, FY26, came in at ₹2,951 Cr. The last four reported quarters add to ₹2,950 Cr.
FY26 revenue came in at ₹2,951 Cr (+12.5% on the year), capping 10 years at 12.7% compound. The latest quarter (Mar 26) printed ₹856 Cr, +20.9% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +12.1% growth against the decade's 12.7% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +12.5% over the last 4 quarters against +16.4%/yr over the last 8 — rolling over; TTM profit +9.7% vs +15.5%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 23.0% this quarter (+5.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Marksans Pharma Ltd's operating margin is 23.0% in the Mar 26 quarter, +5.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0% to 25.0%. The current quarter sits inside that band.
Marksans Pharma Ltd's operating margin is 23.0% in the Mar 26 quarter, +5.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0% to 25.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 23.0%, +5.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0%–25.0%.
Why the margin moved: operating margin went +4.9 pp year on year while gross margin went +0.3 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins held — did that reach the bottom line? Next: profit +63.7% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Marksans Pharma Ltd earned ₹149 Cr of net profit in the Mar 26 quarter, +63.7% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹420 Cr. The 10-year compound rate is 17.6%. That is 17.4% of the quarter's revenue. The same quarter a year earlier earned ₹91.0 Cr.
Marksans Pharma Ltd earned ₹149 Cr of net profit in the Mar 26 quarter, +63.7% year on year. It is the 3rd consecutive quarter of growth. Full-year FY26 profit was ₹420 Cr. The 10-year compound rate is 17.6%. That is 17.4% of the quarter's revenue. The same quarter a year earlier earned ₹91.0 Cr.
Mar 26 profit was ₹149 Cr, +63.7% year on year — the 3rd consecutive quarter of growth. On the full year, FY26 printed ₹420 Cr (+9.7%), and the 10-year compound rate is 17.6%.
Why profit moved: revenue contributed +20.9% and the margin +5.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +9.6% vs revenue +12.1%. Profit and revenue are moving roughly in step.
→ Profit rose — but did the cash follow? Next: 80% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 80% of Marksans Pharma Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹458 Cr of operating cash against ₹420 Cr of profit. After ₹193 Cr of capital spending, ₹265 Cr was left as free cash.
FY26: operating cash of ₹458 Cr against reported profit of ₹420 Cr, leaving free cash of ₹265 Cr after ₹193 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 80% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 80%: the cash cycle stretched 44 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 3.4× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹863 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Marksans Pharma Ltd's cash conversion cycle runs 261 days in FY26, up from 217 days in FY21. Capital spending ran ₹863 Cr over the last 3 years. At FY26 sales of ₹2,951 Cr each day of that cycle holds about ₹8.1 Cr, so roughly ₹2,110 Cr sits inside the business at any moment.
FY26: debtors at 80 days, inventory at 278 days — roughly 9.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 261 days, looser than FY21's 217.
The full loop: cash goes out to suppliers and production on day 0; stock waits 278 days to sell; customers pay about 80 days after that; and suppliers themselves are paid at 96 days — netting out to the 261-day cycle.
In money terms: at FY26 sales of ₹2,951 Cr, each day of the cycle holds about ₹8.1 Cr — so the 261-day loop keeps roughly ₹2,110 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹863 Cr over the last 3 fiscal years against ₹256 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹15.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 19% and the ROIC − WACC spread is +3.7 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Marksans Pharma Ltd earns a ROCE of 19% in FY26. That is up from a trough of 4% in FY17. Return on invested capital clears the cost of that capital by +3.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.2% net margin on 0.76× asset turns.
FY26 ROCE is 19%, recovered from a FY17 trough of 4% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 14.2% net margin × 0.76× asset turns × 1.28× balance-sheet leverage ≈ 13.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 15.7% − 12.0% = a +3.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.11.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Marksans Pharma Ltd carries total debt of ₹343 Cr against shareholder equity of ₹3,053 Cr as of Mar 26, a debt-to-equity of 0.11 — effectively unlevered. On the annual view that ratio went from 0.09 in FY22 to 0.11 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹343 Cr against shareholder equity of ₹3,053 Cr — a debt-to-equity of 0.11. On the annual view, debt-to-equity went from 0.09 (FY22) to 0.11 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 2.4 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 2.4 points of Marksans Pharma Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 6.2% of the company. Foreign institutions moved −1.1 points over the same window, to 17.5%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +2.4 points over 8 quarters to 6.2%; Foreign institutions: −1.1 points over 8 quarters to 17.5%; Promoters: +0.0 points over 8 quarters to 43.9%.
Why the register moved: domestic institutions drove it (+2.4 points), absorbed on the other side by foreign institutions (−1.1 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Marksans Pharma Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Marksans Pharma Ltd this page | 26.7× | ₹11,161 Cr | Consistent | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Marksans Pharma Ltd's share price today?
Marksans Pharma Ltd trades at ₹267, +4.4% over the past year. The company is valued at ₹11,161 Cr. The stock sits at 95% of its 52-week range of ₹163–₹272, +26.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 8 weeks in. — as of 24 July 2026.
What were Marksans Pharma Ltd's latest quarterly results?
Marksans Pharma Ltd reported revenue of ₹856 Cr and net profit of ₹149 Cr for the Mar 26 quarter. Revenue rose 20.9% and profit rose 63.7% year on year. Earnings per share were ₹3.27. The operating margin was 23.0%, 5.0 pp higher than a year earlier. — as of 24 July 2026.
What is Marksans Pharma Ltd's revenue?
Marksans Pharma Ltd reported revenue of ₹856 Cr in the Mar 26 quarter, +20.9% year on year. For the full FY26 fiscal year, revenue was ₹2,951 Cr (+12.5%). Over the last 10 years revenue compounded at 12.7% a year. — as of 24 July 2026.
What is Marksans Pharma Ltd's profit?
Marksans Pharma Ltd earned ₹149 Cr of net profit in the Mar 26 quarter, +63.7% year on year — the 3rd straight quarter of growth. Full-year FY26 profit was ₹420 Cr. The operating margin ran 23.0% in the latest quarter. — as of 24 July 2026.
What is Marksans Pharma Ltd's market cap?
Marksans Pharma Ltd's market capitalisation is ₹11,161 Cr at a share price of ₹267. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Marksans Pharma Ltd's P/E ratio?
Marksans Pharma Ltd trades at a P/E of 26.7×, at the 69th percentile of its own 10-year range, against a long-run median of 20.9×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Marksans Pharma Ltd pay a dividend?
Yes — Marksans Pharma Ltd's dividend payout was 10% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Marksans Pharma Ltd overvalued?
On its own history, Marksans Pharma Ltd looks expensive against its own history: its P/E of 26.7× sits at the 69th percentile of its 10-year range (long-run median 20.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Marksans Pharma Ltd growing?
Yes — Marksans Pharma Ltd is growing: latest-quarter revenue +20.9% year on year, profit +63.7%, and the margin +5.0 pp at 23.0%. The 10-year compound rates are 12.7% (revenue) and 17.6% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Marksans Pharma Ltd performing?
Marksans Pharma Ltd is in a confirmed uptrend, 8 weeks in. Its latest quarter's revenue rose 20.9% and profit rose 63.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 23 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Marksans Pharma Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 19.2% and holding. The read comes from the last 12 quarters of growth (revenue growth +12.5% latest, profit growth +9.7% latest, eps growth +9.9% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Marksans Pharma Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 8 of stage 2), trading +26.3% versus its 200-day average and at 95% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Marksans Pharma Ltd beating the market?
On recent form, yes — Marksans Pharma Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 23 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +428% against the NIFTY 500's +274% — ahead of the index over the full window. — as of 24 July 2026.
Will Marksans Pharma Ltd's share price go up?
This page publishes no price forecast for Marksans Pharma Ltd. What it measures instead: the share price is ₹267, the price is in a confirmed uptrend 8 weeks in. Its P/E of 26.7× sits at the 69th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Marksans Pharma Ltd?
Promoters hold 43.9% of Marksans Pharma Ltd, foreign institutions 17.5%, domestic institutions 6.2% and the public 32.5% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 2.4 points over 8 quarters. — as of 24 July 2026.
Does Marksans Pharma Ltd have too much debt?
No — Marksans Pharma Ltd's debt-to-equity is 0.11, and operating profit covers the interest bill 25×. FY26 borrowings were ₹343 Cr against equity of ₹3,023 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Marksans Pharma Ltd's capex?
Marksans Pharma Ltd spent ₹863 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹193 Cr, with ₹15.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Marksans Pharma Ltd's cash flow?
Marksans Pharma Ltd generated ₹458 Cr of operating cash flow in FY26 and ₹265 Cr of free cash flow after ₹193 Cr of capital spending. Reported profit that year was ₹420 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Marksans Pharma Ltd's profit real cash?
Yes — over the last 3 fiscal years, 80% of Marksans Pharma Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹458 Cr against reported profit of ₹420 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Marksans Pharma Ltd in its business cycle?
Marksans Pharma Ltd's FY26 operating margin was 20.0%, against a 13-year band of 6.0%–25.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 23.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Marksans Pharma Ltd story?
Biggest watch item: the P/E sits at the 69th percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Marksans Pharma Ltd a stock worth studying right now?
This is not investment advice. The machine read: Marksans Pharma Ltd's earnings have outrun its stock. EPS grew +9.8% in a year against a +4.4% price move. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.